Testosterone, Testosterone Replacement Therapy, and Cardiovascular Disease: A Contemporary Review
Journal of the American Heart Association · 03.11.2026 · 15 (21)
DOI: 10.1161/jaha.126.054307 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of the American Heart Association, erschienen am 03.11.2026. Verfasst von Anand Reddy Maligireddy und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine University of Kansas Medical Center Kansas City KS USA. Hauptthemen laut MEDLINE: Testosterone, Cardiovascular Diseases, Hormone Replacement Therapy, Hypogonadism. Die Arbeit nennt 65 Literaturangaben.
Abstract (Originalsprache)
Whether low endogenous testosterone is causal for cardiovascular disease, and how the cardiovascular risk of testosterone replacement therapy should now be classified, remain contested, while US labeling has moved in 2 opposing directions within 16 months. We conducted a targeted narrative review reported in accordance with the Scale for the Assessment of Narrative Review Articles, searching MEDLINE and primary regulatory documents from January 2000 through July 2026. Evidence was graded with a prespecified 3‐tier structured author‐consensus rating separating established randomized findings, unresolved secondary signals, and evidentiary absence. Low endogenous testosterone is consistently associated with higher all‐cause and cardiovascular mortality but most plausibly marks multimorbidity rather than causation. TRAVERSE established that physiologic transdermal testosterone replacement therapy was noninferior to placebo for 3‐point major adverse cardiovascular events over ∼3 years, within a permissive margin and against a 61% discontinuation rate. Observational analyses linking normalization to lower mortality were not reproduced under randomization. Atrial fibrillation, pulmonary embolism, acute kidney injury, fracture, and noncalcified plaque progression remain unresolved. Blood pressure rises across the class; on ambulatory monitoring the magnitude differs by individual product rather than by route. Long‐term exposure and nontransdermal formulations remain untested, and the age‐related‐hypogonadism limitation of use is now proposed for removal. Noninferiority over 3 years should not be read as long‐term clinical equivalence. Safe use of testosterone replacement therapy requires appropriate patient selection, distinction between pathologic hypogonadism and functional or age‐associated low testosterone, mapping of each recommendation to its evidentiary tier, and close multidisciplinary collaboration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine University of Kansas Medical Center Kansas City KS USA.
- Division of Cardiovascular Research Kansas City Veterans Affairs Medical Center Kansas City MO USA.
- Division of Cardiovascular Medicine Kansas City Veterans Affairs Medical Center Kansas City MO USA.
ORCID-Profile: Anand Reddy Maligireddy, Rajat S Barua
Zitieren
APA
Maligireddy, A. R., Barua, S. T., & Barua, R. S. (2026). Testosterone, Testosterone Replacement Therapy, and Cardiovascular Disease: A Contemporary Review. Journal of the American Heart Association, 15(21). https://doi.org/10.1161/jaha.126.054307
Vancouver
Maligireddy AR, Barua ST, Barua RS. Testosterone, Testosterone Replacement Therapy, and Cardiovascular Disease: A Contemporary Review. Journal of the American Heart Association. 2026;15(21). doi:10.1161/jaha.126.054307
BibTeX
@article{Maligireddy2026,
author = {Maligireddy, Anand Reddy and Barua, Shumedha T and Barua, Rajat S},
title = {Testosterone, Testosterone Replacement Therapy, and Cardiovascular Disease: A Contemporary Review},
journal = {Journal of the American Heart Association},
year = {2026},
volume = {15},
number = {21},
doi = {10.1161/jaha.126.054307}
}
EUVIMED